Correspondence 0001214659-24-012037 from Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc.
Date: July 8, 2024 · CIK: 0001677077 · Accession: 0001214659-24-012037
AI Filing Summary & Sentiment
File numbers found in text: 333-279920
Letter
ALZAMEND NEURO, INC.
3480 Peachtree Road NE
Second Floor, Suite 103
Atlanta, GA 30326
July 8, 2024
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Lauren Hamill and Chris Edwards
Re: Alzamend Neuro, Inc.
Registration Statement on Form S-1
File No. 333-279920
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Alzamend Neuro, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 pm, Eastern Time, on July 9, 2024, or as soon thereafter as possible.
Please notify Henry C.W. Nisser, General Counsel of the Company, at (646) 650-5044 as soon as possible as to the time the registration statement has been declared effective pursuant to this acceleration request.
ALZAMEND NEURO, INC.
By: /s/ Stephan Jackman
Name: Stephan Jackman
Title: Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
ALZAMEND NEURO, INC.
3480 Peachtree Road NE
Second Floor, Suite 103
Atlanta, GA 30326
July 8, 2024
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Lauren Hamill and Chris Edwards
Re: Alzamend Neuro, Inc.
Registration Statement on Form S-1
File No. 333-279920
Ladies and Gentlemen:
Pursuant to Rule 461 of the
General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Alzamend Neuro, Inc. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective
at 4:00 pm, Eastern Time, on July 9, 2024, or as soon thereafter as possible.
Please notify Henry C.W. Nisser,
General Counsel of the Company, at (646) 650-5044 as soon as possible as to the time the registration statement has been declared effective
pursuant to this acceleration request.
ALZAMEND NEURO, INC.
By:
/s/ Stephan Jackman
Name:
Stephan Jackman
Title:
Chief Executive Officer